Access to the full text of the published version may require a subscription. The data demonstrate that the S1P analogue, FTY720, adversely affects the immune response and clearance of C. rodentium.
INTRODUCTION
Therapeutic use of the Sphingosine 1-Phosphate (S1P) analogue FTY720 [Gilenya (fingolimod)] has proven efficacy in patients with multiple sclerosis (MS), and was recently approved by the US Food and Drug Administration as a first line treatment for relapsing forms of the disease (1, 27) . FTY720 modulates S1P signalling, preventing lymphocyte egress from the thymus and spleen into the blood and from the lymph nodes (LNs) into the lymph, thus blocking lymphocyte trafficking to target tissues (5, 6, 16) . It also affects dendritic cell (DC) migration (31) , modulates DC pro-inflammatory signalling, and is a potent inhibitor of regulatory T cell (Treg) proliferation (56) .
Controversy surrounds the complex mechanism of action of FTY720 in vivo and it is unclear whether it acts as an agonist or functional antagonist or both during regulation of lymphocyte recirculation (21, 47, 52, 58) . FTY720 ameliorated disease in numerous pre-clinical models of colitis including those induced by oxazolone (12) , TNBS (11), DSS (14) , adoptive transfer (14, 18) and in IL-10 deficient mice (36) . In addition, it was therapeutically efficacious in graft versus host disease (24) and in clinical studies of transplantation and MS (2, 4, 23) . However, treatment with FTY720 may increase the risk of mucosal infections and its effect on host immune responses upon exposure to such threats has yet to be completely elucidated. Two fatal herpes virus infections were reported in a clinical phase 3 study comparing FTY720 with IFN-β, (7, 19) , and an increased incidence of respiratory tract infections, such as bronchitis, have been reported in MS patients with FTY720 treatment (8, 28) . Nonetheless, studies to date assessing the effect of FTY720 on innate and adaptive immune responses have specifically focused on exposure to viral antigens and vaccines (30, 35) . There are no studies examining the effect of FTY720 treatment following exposure to gastrointestinal infections.
In the current study, we assess the effect of continuous dosing of FTY720 on susceptibility of mice to Citrobacter rodentium (C. rodentium), a commonly used noninvasive enteropathogen, which is a model for human enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC) infection. C. rodentium intimately attaches to the apical surface of the gut epithelium, inducing epithelial cell actin rearrangements and localized destruction of brush border microvilli and leading to the formation of underlying pedestal-like attaching/effacing (A/E) lesions in the host cell (29) . Oral infection of immunocompetent mice with C. rodentium leads to a transient colonisation and inflammation that peaks after one week and is cleared in the ensuing two to three weeks (37) . Bacterial colonization is limited to the intestinal mucosa with low bacterial burden in systemic organs. The mice exhibit mild signs of clinical disease and microscopically the mucosa presents crypt hyperplasia, goblet cell loss and mucosal infiltration of immune cells including T cells, macrophages and neutrophils. For efficient bacterial clearance a robust Th1 host immune response is required, mediated by infiltrating CD4 + T cells and macrophages. Thus, C. rodentium infection is an excellent model to investigate host-bacterial immune interactions in the intestine. In addition, the availability of a bioluminescent strain that allows pathogen burden and clearance dynamics to be followed in vivo using bioluminescence imaging makes this model a versatile tool (9, 17, 40) . Our data clearly show that continuous treatment with FTY720 delays clearance of C. rodentium infection in mice, by blocking the migration of T cells and other immune cells to the inflamed colon. Host protective mucosal immunity is altered with impairment of innate and adaptive immune responses. This is the first report, to our knowledge, that FTY720 can compromise critical host defence against commonly encountered enteric pathogens.
MATERIALS AND METHODS

Mice
Specific pathogen-free female C57BL/6OlaHsD mice, 7-12 wk old, weighing [17] [18] [19] [20] g, were obtained from Harlan, UK. All mice were housed in individually ventilated cages (IVCs, OptiMICE, Animal Care Systems, UK) in groups of 3-4 mice per cage, with sterile bedding, temperature 21°C, 12h light: 12h darkness, humidity 50% in a dedicated animal holding facility. They were fed a sterilized pellet diet and tap water ad libitum. Mice were allowed ≥2 wk to acclimatize before entering the study. All animal procedures were performed according to national ethical guidelines following approval by University College Cork Animal Experimentation Ethics Committee (AEEC).
Citrobacter rodentium-induced colitis
The bioluminescent C. rodentium strain ICC180, was a gift from Prof. Gordon Dougan (Wellcome Trust Sanger Institute, UK). This nalidixic acid (NA)-resistant strain harbors a constitutively expressed luminescent tag that enables the colonization pattern to be followed by bioluminescence imaging. Previous studies have shown strong correlation between cell numbers and bioluminescent signals (15, 43) .
Similarly, light levels emitted by bioluminescent C. rodentium strains have been shown to accurately reflect the bacterial numbers in vivo (55) . C. rodentium strain ICC180 was cultured overnight in Luria-Bertani (LB) broth supplemented with NA (50µg/ml) (Sigma-Aldrich Ltd, Dublin, Ireland) @ 37°C, centrifuged @ 3000 g for 10 min and re-suspended in 10ml of sterile phosphate buffered saline (PBS) for oral gavage. Each mouse received 200μl (approximately 5 x 10 9 bacteria) of the bacterial suspension. Post-gavage, the remainder of the suspension was plated in serial dilutions for retrospective enumeration. For bacterial enumeration in the stool collected at different time-points, serial dilutions of a fecal/PBS suspension (neat to 10 -7 ) were plated onto supplemented LB agar using a spot-plate technique and incubated overnight @ 37°C. To determine bacterial number in the spleen, the organ was weighed, manually crushed in 2ml of PBS in a stomacher bag, plated using serial dilutions onto supplemented LB agar and incubated overnight @ 37°C.
FTY720 administration
To assess the effect of continuous dosing of FTY720 on C. rodentium-induced colitis, mice were orally gavaged with vehicle (1% methylcellulose, Sigma-Aldrich Ltd, Dorset, England) or 3mg/kg FTY720 for 6 days pre-infection (day -6 to day -1 inclusive). Mice were orally gavaged with C. rodentium on day 0 and vehicle/ FTY720 dosing was continued every 2 nd day from day 1 up until day 12 post-infection (p.i.). Mice were sacrificed at two time-points on day 8 (peak infection) and on day 14
(late infection/ clearance). The number of mice per group per time-point was 7. Noninfected controls were dosed with vehicle and FTY720 according to the same regime, n=4 per group. The FTY720 compound was kindly provided by Dr. A. Haynes (GlaxoSmithKline, Stevenage, UK).
In a separate study, we investigated the effect of stopping FTY720 dosing during early C. rodentium infection. In this instance, as with the continuous dosing study, the mice were orally gavaged daily with vehicle (1% methylcellulose) or 3mg/kg FTY720 for 6 days pre-infection (day -6 to day-1 inclusive). Following infection on day 0, dosing was continued for only 2 days. Mice were sacrificed on day 14. Number of mice per group was 7.
Clinical assessment of inflammation
Body weight was monitored regularly. Clinical assessment of inflammation was adapted from other colitis models (38, 39) . Briefly, stool consistency (0=normal, wellformed pellets, 1=changed formed pellets, 2=loose stool, 3=diarrhea) and fur texture/posture (0=smooth coat/ not hunched, 1=mildly scruffy/mildly hunched, 2=very scruffy/very hunched) were recorded every 2 nd day for the duration of the study to generate a disease activity index.
In vivo bioluminescence imaging
On day 8 and 14 p.i., in vivo bioluminescence imaging was performed as previously described (10, 51) , using an IVIS 100 charge-coupled device imaging system (Xenogen, Alameda, CA). Briefly, following gaseous anesthesia with 3% isoflurane, the animals were transferred to the imaging chamber where emission images were collected with 5 min integration times. Following the whole-body imaging, the mice were euthanized via cardiac puncture. The colons were removed, detached from the caecums, cut longitudinally, washed in PBS and imaged for 5 min. The caecums were also washed in PBS prior to imaging. The mesenteric lymph nodes (MLNs) and spleens were removed and imaged. Bioluminescent signal was quantified by creation of regions of interest (ROIs). To standardize the data, light emission was quantified from the same surface area (ROI) for each organ type. In addition, background light emission, taken from ROIs created on organs of non-infected control animals, was subtracted from test organs. Imaging data was analyzed and quantified with Living
Image Software (Xenogen) and expressed as photons/second/cm 2 .
Histology
The colons were removed, opened longitudinally, washed in PBS and separated into proximal and distal sections. The length of each colon was measured and 3cm was taken as the distal. The proximal and distal colons were weighed, cut longitudinally and one section of the distal was processed as a ''Swiss roll'' and snap frozen in OCT compound (Tissue-Tek, Sakura Finetek, USA) using liquid nitrogen. Frozen colons were cryo-sectioned (6μm), fixed for 5 min in ice-cold acetone/ethanol (3:1 ratio) and stained with haematoxylin and eosin according to standard histological procedures.
Colon sections were evaluated and assigned scores in a blinded fashion for evidence of inflammatory damage such as goblet cell loss, crypt elongation, mucosal thickening and epithelial injury including hyperplasia and enterocyte shedding into the gut lumen. Scores were determined for four fields of view per mouse at 20x magnification (Olympus BX51, Germany) based on a scale of 0-3 (0=none, 1=mild, 2=moderate, 3=severe). A mean inflammatory score was then assigned per mouse distal colon, n= 3-4 mice per group.
Immunofluorescent staining
Frozen colon and MLN sections (6μm) were fixed in ice-cold acetone/alcohol mix (3:1 ratio), blocked with blocking serum for 45 min at room temperature in a humidified chamber and stained with combinations of the mAbs listed in Table 1 .
Purified mAbs were counter-stained using the appropriate AlexaFluor488-conjugated anti-Ig antibody (Invitrogen, BioSciences Ltd, Ireland). Hoechst (Invitrogen) was used as a nuclear counter-stain. Stained sections were mounted in ProLong Gold antifade reagent (Invitrogen) and were coded and visualized using a fluorescent microscope (Olympus BX51, Germany) in a blinded fashion. For cell number quantitation, 7-10 fields of view were counted @ 40X for 3-4 mice per group.
Flow Cytometry
Blood was harvested from the mice via cardiac puncture on day 8 and day 14 into 
RNA extraction and quantitative RT-PCR (qRT-PCR)
Colonic mucosal mRNA expression was evaluated using qRT-PCR. The distal colons were weighed, cut longitudinally and one section was snap frozen in 1ml RNA later.
Frozen colonic tissue samples were thawed on ice and transferred to magnalyser tubes with green beads (Roche Ireland Limited, Clare, Ireland) containing 1ml of lysis buffer (provided by mirVana kit, Ambion, Applied Biosystems). Samples were homogenized (x3) @ 6,500 g for 15 seconds using a Magnalyser Instrument (Roche).
Homogenized samples were centrifuged @ 200 g for 5 min @ 4°C and the supernatants were stored @ -80°C. Total RNA was isolated from colonic tissue homogenates using mirVana Kit, according to the manufacturers' protocol. RNA purity was measured by spectrophotometric analysis using a nanodrop.
Complementary DNA (cDNA) was synthesized using 1μg total RNA. PCR primers and probes were designed using the Universal ProbeLibrary Assay Design Centre 
Statistical Analysis
Data are represented by Mean ± SEM unless otherwise stated. The specific tests used are as indicated in the figure legends. All statistical tests were performed using commercially available statistic software (GraphPad Software Inc, CA). A P value of < 0.05 was considered significant.
RESULTS
FTY720 induces peripheral blood lymphopenia by trapping lymphocytes within the LNs
The effect of FTY720 on blood immune cell populations in C. rodentium infected mice was assessed at various time-points during the treatment period using flow cytometry. A significant reduction of T cells in the blood (lymphopenia) was observed in the FTY720-treated animals, compared to those that received vehicle on day 8 and day 14 p.i. (Fig. 1A) , in accordance with previous reports (35) . A similar reduction was observed with levels of B cells on day 8, but not on day 14 p.i. (Fig. 1A) .
Additionally, a significant increase in DCs was observed in the blood of the FTY720-treated mice on day 14 p.i., but not on day 8 p.i. (Fig. 1A) . FTY720 treatment appeared to have no effect on levels of blood granulocytes (Fig. 1A) confirming the inhibitory effect of the S1P analogue on their egress from secondary lymphoid organs (Fig. 1B) .
FTY720 treatment increases pathogen burden and impairs bacterial clearance
To determine the effects of FTY720 on C. rodentium infection in mice, we visualized and quantitated levels and tissue distribution of the pathogen on day 8 and day 14 p.i.
using bioluminescence imaging. Whole-body imaging revealed a high pathogen burden in the lower abdominal/ gastrointestinal region of both the vehicle-treated and FTY720-treated mice on day 8 p.i. (Fig. 2A) . However, the bioluminescent signal from the FTY720-treated animals was significantly higher (p<0.001, Fig. 2A and C) .
On day 14 p.i., while whole-body imaging revealed clearance of the bacteria by the infected vehicle-treated mice, as evidenced by a significantly diminished bioluminescent signal, no such clearance was evident in the infected FTY720-treated mice ( Fig. 2B and C) . Ex vivo bioluminescence imaging of the organs on day 8 p.i.
revealed significantly higher colonization of caecums (p<0.05), colons (p<0.05), spleens (p<0.01) and MLNs (p<0.001) of the FTY720-treated mice compared to the vehicle-treated (Fig. 2D) . C. rodentium initially infects the caecum and then moves onto the distal colon. We and others have confirmed this colonisation pattern using bioluminescence (55) . In the present study, 100% of the FTY720-treated mice had evidence of bacteria in the caecum on day 8 p.i., compared to 28% of those that received vehicle. By day 14 p.i., in contrast to the vehicle-treated mice, the signal from the colons and caecums remained high in the FTY720-treated animals and there was evidence of MLN infection in just under half of the mice (Fig. 2D ). The bioluminescence data were supported by fecal cfu counts, which were performed at various time-points p.i.. These confirmed that day 8 was close to peak infection (Fig.   2E ). In addition, FTY720-treated mice shed significantly higher numbers of C.
rodentium in their stool from day 9 p.i. on, compared with vehicle-treated controls, and showed no signs of clearing the infection. Bacterial numbers in the feces of the drug-treated animals continued to increase over-time (Fig. 2E) , while those of the vehicle-treated animals began to drop after day 7 p.i.. Splenic bacterial counts were similar between vehicle-treated and FTY720-treated animals on day 8 p.i.. However, on day 14 p.i. the vehicle-treated animals no longer had any evidence of bacterial growth in this organ, while bacterial burden in the spleen of mice receiving the S1P analogue remained high (Fig. 2F) . In contrast to vehicle-treated mice, FTY720-treated animals did not resolve the infection by day 14 p.i. and still had high concentrations of bacteria in all organs analyzed.
FTY720 treatment exacerbates clinical and colonic pathology during C. rodentium infection
To determine the effect of FTY720 administration on disease during C. rodentium (p<0.001) (Fig. 3A) . Moreover, no differences in distal colonic weights were observed between vehicle-treated and FTY720-treated non-infected controls (Supplementary Figure 1B) . In contrast, C. rodentium-infected mice that received FTY720 had heavier distal colons, than those treated with vehicle on day 14 p.i., suggesting increased inflammation. This observation was supported by histological analysis of the distal colons, which revealed significantly increased inflammatory score, i.e. higher mucosal thickening, epithelial cell hyperplasia and goblet cell depletion, in the infected FTY720-treated mice compared to infected vehicle-treated controls ( Fig. 3B and C) . Although signs of inflammation and tissue damage were evident in the vehicle-treated colons compared to the non-infected colons at day 14 p.i., it was much less severe and resolution and epithelial healing appeared to be taking place.
FTY720 alters the composition of immune cell populations infiltrating the colon during C. rodentium infection
To determine the effect of FTY720 on the composition and distribution of immune (Fig. 4A and B) . In comparison to the vehicle-treated animals, T and B lymphocytes (p<0.01, p<0.001), DCs (p<0.01) and macrophages (p<0.001) were significantly decreased in the distal colons of FTY720-treated animals at this time-point ( Fig. 4A and B) . However, the numbers of neutrophils were significantly increased (p<0.05) in these mice ( Fig. 4A and B) .
FTY720 treatment down-regulates genes associated with the mucosal immune response to C. rodentium
To assess the effect of FTY720 treatment on the expression of innate and adaptive immune-modulatory genes during C. rodentium infection, distal colonic RNA was isolated and mRNA expression was evaluated using qRT-PCR. In the distal colons of C. rodentium-infected animals that received vehicle, expression levels of innate immune genes, such as the pro-inflammatory mediators IL-1β, iNOS and TNF-α, were significantly up-regulated compared to non-infected controls at day 8 p.i.. This up-regulation was significantly decreased in FTY720-treated animals compared to vehicle-treated (Fig. 5A ). In contrast, on day 14 p.i. the expression of these mediators, together with IL-17a and IL-6, was significantly up-regulated in the drug-treated animals compared to vehicle-treated controls at this time point (Fig. 5A) . Similarly, TNF-α was also increased in these mice at this time point (p=0.053). To determine what effect termination of FTY720 dosing has during early C.
rodentium infection, mice were administered vehicle or the S1P analogue daily for 6 days prior to C. rodentium infection and 2 days after infection. On day 14 p.i., blood leukocyte populations, colonization and clinical and macroscopic markers of infection were determined. In the infected mice that had been treated with FTY720, peripheral blood lymphopenia was maintained, as were the enhanced numbers of DCs (Fig. 6A) .
Unlike with continuous dosing p.i., blood levels of peripheral granulocytes and NK cells were increased compared to the infected vehicle-treated mice (Fig. 6A) . Wholebody bioluminescence imaging revealed that the FTY720-treated mice were still heavily colonized by day 14 p.i. and had higher signals from their colon (p<0.001, Fig. 6C and D) , caecum (p<0.001, Fig. 6C and Supplemental Fig. 3 ), MLNs and spleen (p<0.001, Supplemental Fig. 3 ). These data were supported by faecal cfu counts (Fig. 6E) . However, no differences in disease activity or distal colon weight were evident between the infected vehicle-treated group and those that had received FTY20.
Discussion
The results of this study show that FTY720 delayed clearance of the murine enteric pathogen C. rodentium. This was most likely a result of FTY720-mediated peripheral lymphopenia and T cell entrapment within the lymph nodes resulting in impairment of the adaptive immune response within the colon. Additionally, the colonic innate immune response was impaired and there was increased colon pathology and bacterial dissemination.
Our data show that FTY720 induced peripheral blood lymphopenia pre-and postinfection and T cell entrapment within the MLNs, which is consistent with previous reports (1, 3) . Data from bioluminescence imaging of whole-body and organs combined with viable bacterial counts of the stool and spleen revealed that FTY720-treated mice were highly susceptible to colonic and systemic infection with C.
rodentium. In addition to increased bacterial burden, more extensive pathogen distribution and impaired bacterial clearance, these mice exhibited higher disease activity at peak infection and greater colonic pathology at day 14 p.i.. These findings are in contrast to what has been previously demonstrated in experimental models of colitis reflecting IBD (11, 12, 14, 18, 36) . In these instances, FTY720 had a therapeutic effect on disease by blunting immunity. In the present study, FTY720
blocked lymphocyte migration to the C. rodentium-infected intestine. Notably, FTY720-treated mice had reduced numbers of colonic T cells, DCs, B cells and macrophages, but increased numbers of neutrophils at day 14 p.i. when compared to vehicle-treated infected controls. These results are reminiscent of those observed in T and B cell deficient RAG1 knockout (KO) mice (45) . In fact, C. rodentium infection in these mice also leads to a predominantly granulocytic colonic infiltrate and enhanced bacterial presence in peripheral organs as well as colons (34, 45, 54) .
Neutrophils are important in the early innate immune response to infection such as C.
rodentium, preventing dissemination and controlling bacterial load (32, 50) . However, during chronic inflammatory disease they can contribute to host tissue pathology (26, 41, 49) . In the present study, increased neutrophil presence in the infected colons of FTY720-treated mice at day 14 p.i. was accompanied by enhanced severity of colonic inflammation. Interestingly, this increased neutrophil influx was also associated with up-regulated expression of the innate immune-related genes IL-1β, iNOS, IL-17a, IL-6 and TNF-α at day 14 p.i.. In agreement with previous reports, we found that gene expression of these innate immune cytokines was elevated in infected vehicle-treated mice compared to non-infected controls at peak infection (22, 48) . These cytokines play a significant role in host defense and clearance of C. rodentium during early infection (13, 20, 25, 53) . In the present study, it is possible that the innate immune response may be attempting to compensate for the blunted adaptive response in the infected FTY720-treated colons at day 14 p.i (32) . Another possibility is that FTY720
is impairing the innate immune response at peak infection; a notion supported by the down-regulation of these cytokines in the FTY720-treated colons compared to vehicle-treated at day 8. The fact that the delayed innate response is unsuccessful at day 14 p.i. does not preclude the possibility that at later time-points, the heightened neutrophilic response may eventually promote clearance of C. rodentium. However, it should be noted that long-term infected RAG1KO mice (up to day 60 p.i.) also fail to clear C. rodentium infection (54) . Importantly, we also demonstrated that termination of FTY720 treatment early after infection had little or no effect on pathogen clearance or immune profiles. This data highlights that within a clinical setting; even with early diagnosis of infection, patients might still be highly susceptible to disease for at least two weeks or longer after termination of drug treatment.
To our knowledge, this is the first study investigating the effect of FTY720 treatment 
